8-K: Liquidia Faces New Patent Infringement Lawsuit from United Therapeutics Over YUTREPIA

Liquidia Corporation is facing a lawsuit from United Therapeutics Corporation alleging infringement of a patent related to YUTREPIA, Liquidia's investigational drug for pulmonary hypertension.

Summary

• Liquidia Corporation announced that United Therapeutics Corporation (UTHR) filed a complaint on May 9, 2025, alleging infringement of U.S. Patent No. 11,357,782.
• The lawsuit seeks to prevent Liquidia from commercializing YUTREPIA (treprostinil) inhalation powder if it receives FDA approval for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
• UTHR is not seeking an injunction against the FDA to prevent final approval of the New Drug Application (NDA) for YUTREPIA.
• The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2025, for YUTREPIA.
• Liquidia's CEO, Dr. Roger Jeffs, stated that the company will defend the rights of patients to choose the therapy that works best for them.
• Liquidia believes the '782 patent claims the same general method of administering inhaled treprostinil as U.S. Patent No. 10,716,793, which was previously invalidated.

Sentiment

Score: 4

Explanation: The news is negative due to the lawsuit, but Liquidia expresses confidence in its ability to defend against it. The lack of an injunction against the FDA is a slight positive.

Positives

• United Therapeutics is not seeking an injunction against the FDA to prevent final approval of YUTREPIA.
• Liquidia has previously invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil.

Negatives

• Liquidia is facing a patent infringement lawsuit from United Therapeutics, which could delay or prevent the commercialization of YUTREPIA.
• The lawsuit introduces uncertainty regarding the future of YUTREPIA.

Risks

• The outcome of the patent litigation could significantly impact Liquidia's ability to commercialize YUTREPIA.
• An unfavorable ruling could result in an injunction preventing Liquidia from selling YUTREPIA.
• The litigation process could be costly and time-consuming for Liquidia.

Future Outlook

The future of YUTREPIA hinges on the outcome of the patent litigation with United Therapeutics and the FDA's decision on the New Drug Application (NDA).

Management Comments

• Dr. Roger Jeffs, CEO, Liquidia said: 'We are not surprised by UTHRs repeated, last-minute attempts to deny PAH and PH-ILD patients access to an alternative therapy.'
• Dr. Roger Jeffs, CEO, Liquidia said: 'We have invalidated similar claims covering the treatment of pulmonary hypertension patients with inhaled treprostinil in the past and will continue to defend the rights of patients suffering with these critical illnesses to choose the therapy that works best for them.'

Industry Context

The lawsuit reflects the competitive landscape in the pulmonary hypertension treatment market, where companies are actively protecting their intellectual property.

Comparison to Industry Standards

• Patent litigation is a common occurrence in the pharmaceutical industry, particularly when dealing with blockbuster drugs or innovative therapies.
• Companies like Teva Pharmaceuticals, Mylan (now Viatris), and Novartis have all been involved in patent disputes related to their products.
• The outcome of these disputes can have significant financial implications for the companies involved, affecting their revenue streams and market share.

Legal Proceedings

• United Therapeutics Corporation filed a patent infringement lawsuit against Liquidia Corporation in the U.S. District Court for the Middle District of North Carolina (Case No. 1:25-cv-00368).

Stakeholder Impact

• Shareholders of Liquidia may experience uncertainty due to the potential impact of the lawsuit on the company's future prospects.
• Patients with pulmonary hypertension could potentially benefit from YUTREPIA if it is approved and commercialized, providing an alternative treatment option.
• The lawsuit could affect Liquidia's employees, depending on the outcome and its impact on the company's operations.

Next Steps

• Liquidia will defend itself against the patent infringement lawsuit filed by United Therapeutics.
• The FDA will continue its review of the New Drug Application (NDA) for YUTREPIA, with a PDUFA goal date of May 24, 2025.

Key Dates

Keywords

YUTREPIA, Liquidia, United Therapeutics, Patent Infringement, Pulmonary Hypertension, Lawsuit, FDA, Treprostinil, PDUFA